Supplement 2. Disclosure of Interest Forms of the Panelists for the American Society of Hematology 2023 Guidelines for Management of Venous Thromboembolism: Thrombophilia Testing

Lisa Baumann-Kreuziger

Michiel Coppens

Damon Houghton

Alfonso Iorio

Andra James

Eddy Lang

Saskia Middledorp

Stephan Moll

Tarra Myers

ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each equity interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each patent or royalty interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes, as described below:

   Column 1 Name the company.

   Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

   Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

   Add rows as needed for each activity.

   To report activities that generate revenues for your institution, see Part B, Question 4.

Company	*Description*	*End Date*	*For ASH Internal Use*

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☐ No

   ☒ Yes, as described below:

   Column 1 Name the company funding or supporting the research.

   Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*
Daiichi Sankyo	Randomized clinical trial of venous thromboembolism in cancer patients	Site-PI	12/31/17	This activity ended before appointment.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

Company	*Description*	*End Date*	*For ASH Internal Use*

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Thrombophilia Guideline Panel

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

   ☒ No

   ☐ Yes

   If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

   ☒ No

   ☐ Yes

   If yes, what were those views and where were they made?

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

   ☒ No

☐ Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Funder	*Description of Research*	*My Role*	*End Date*

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don't know

☐ No

☒ Yes

If yes, please explain:

BloodCenter of Wisconsin performs clinical diagnostic testing for many areas including thrombophilia.

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

Strong support for me to work on this guideline.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☒ No

☐ Yes

If yes, are you involved in formulating or voting for positions?

☐ No

☐ Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

☐ Don't know or not applicable

☐ No

☐ Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

Adult Benign Hematology

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

   ☐ No

   ☒ Yes

   If yes, please explain:

   I perform consultations to determine if thrombophilia testing is needed.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

    ☒ No

    ☐ Yes

    If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publicly available.

Name of guideline panel(s)	Guideline Panel on Thrombophilia

Approved to participate?	*Status*	*Recusal may be required?*	*Reviewer Name and Date*	*Notes*
Yes	Unconflicted majority	No	11/26/2018 Alexander	Dr. Baumann Kreuziger does not have any current financial conflicts of interest.
Yes	Unconflicted majority	No	3/22/2019	New disclosures, see Part D. On 3/21/2019, Dr. Baumann Kreuziger confirmed all information in this form.
Yes	Unconflicted majority	No	1/10/2020	New disclosures, See Part D.
Yes	Unconflicted majority	No	5/8/2020 Alexander	On 5/8/2020, Dr. Baumann Kreuziger confirmed all information in this form.
Yes	Unconflicted majority		3/10/2022 Alexander	New disclosures. See Part D.

If status is conflicted minority, summarize all current material interests in affected companies:

Company	*Description*	*Disclosure Date*	*ASH Notes*

Notes:

Dr. Baumann Kreuziger is an adult benign hematologist and provides clinical consultations to determine if thrombophilia testing is needed.

Part D. New Declarations

The following interests were disclosed after appointment:

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
ACCP	Dr. Baumann discloses participating on the current ACCP VTE guidelines panel.	3/22/2019	**Not a COI.** Dr. Baumann confirmed that the scope of the ACCP guidelines does not overlap with the scope of these guidelines on Thrombophilia.
Quercegen Pharmaceuticals	I have been asked to participate in a protocol writing committee by Jeff Zwicker that will be sponsored by Quercegen Pharmaceuticals. This is for a phase 3 trial of quercegen for prevention of cancer associated thrombosis.	1/10/2020	Not a COI. Quercegen Pharmaceuticals is testing quercetin for prevention of cancer associated thrombosis. However, these guidelines will not address the use of specific anticoagulants.
CSL Behring Advisory	Direct payment for participation in an advisory board.	1/10/2020	Not a COI. CSL Behring markets kcentra (a warfarin reversal agent); however, these guidelines on thrombophilia will not address use of specific anticoagulants.
N/A	Dr. Baumann discloses participating on the NIH COVID-19 guideline panel.	5/22/2020	Not a COI. Dr. Baumann confirmed that the scope of the NIH guidelines does not overlap with the scope of these guidelines on thrombophilia.
N/A	Blood Center of Wisconsin is now called Versiti	3/3/2022	Not a COI. This is an update to Dr. Baumann Krueziger's employer.

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
NIH	Funding for ACTIV-4a, ACTIV-4b, ACTIV-4c trials of anticoagulation in patients with COVID-19. All funds are paid directly to Dr. Baumann Kreuziger's institution.	3/3/2022	Not a COI. The NIH does not produce or market any products used for the testing of thrombophilia. This subject of the trial is unrelated to the guideline topic.
HRSA Vaccine Injury Compensation Program	Direct payment for consulting.	3/3/2022	Not a COI. HRSA does not produce or market any products used for the testing of thrombophilia.
American Society of Hematology	Educational grant from the Moore foundation to develop a VTE metric diagnosis of PE. The grant was paid directly to Dr. Baumann Kreuziger's institution.	3/3/2022	Not a COI. ASH is a not-for-profit organization and does not produce or market any products used for the testing of thrombophilia.
NIH	Funding for the Recipient epidemiology and donor evaluation study-IV-P (REDS-IV-P).	3/3/2022	Not a COI. The NIH does not produce or market any products used for the testing of thrombophilia. This subject of the study is unrelated to the guideline topic.
Northwestern University	Funding for a retrospective study of direct oral anticoagulants in patients at extremes of weight. All funds paid to Dr. Baumann Kreuziger's institution.	3/3/2022	Not a COI. Northwestern University does not produce or market any products used for the testing of thrombophilia. The subject of the study is unrelated to the guideline topic.

ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each equity interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each patent or royalty interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

Company	*Description*	*End Date*	*For ASH Internal Use*

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No

☒ Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*
Daiichi Sankyo	Registry of bleeding complications in patients treated with direct oral anticoagulants (DOACs)	Site investigator	current	No COI. Daiichi Sankyo markets edoxaban; however, these guidelines on thrombophilia are not expected to include recommendations about use of specific anticoagulants. Furthermore, Dr. Coppens does not have a leadership role in this registry.
Sanquin Blood Supply	Efficacy and safety of 4 factor prothrombin complex concentrate as a reversal agent for bleeding in patients treated with DOACs	Site investigator	current	No COI. Sanquin offers diagnostic services, including for blood coagulation and thrombosis. The guidelines may make recommendations about testing;

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*
				however, the subject of this research is unrelated to testing, and Dr. Coppens does not have a leadership role.
Boehringer Ingelheim	Registration (phase 3) trial of idarucizumab as a reversal agent for dabigatran etexilate	Sub-investigator	current	No COI. Boehringer Ingelheim markets dagibatran; however, these guidelines on thrombophilia are not expected to address use of specific anticoagulants Furthermore, the subject of this research (reversal of anticoagulation) is also unrelated to the guideline topic, and Dr. Coppens does not have a leadership role.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

Company	*Description*	*End Date*	*For ASH Internal Use*

Company	*Description*	*End Date*	*For ASH Internal Use*

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Thrombophilia

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

   ☒ No

   ☐ Yes

   If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

   ☐ No

   ☒ Yes

   If yes, what were those views and where were they made?

   I have co-authored (with professor Middeldorp) a chapter on Hereditary Thrombophilia for the upcoming 9th edition of Williams Hematology, an authoritative textbook in Hematology. In this chapter, we present the view that thrombophilia testing is performed often in many clinical circumstances but the necessary consequences of those tests are insufficiently known to warrant such widespread testing.

   A similar opinion is found in four papers which I have (co-)authored:

1. Middeldorp S, Coppens M. Evolution of thrombophilia testing. Hematology Education: the education programme for the annual congress of the European Hematology Association 2013;7(1):375-82
2. Coppens M, Reijnders JH, Middeldorp S, Doggen CJM, Rosendaal FR. Testing for inherited thrombophilia does not reduce recurrence of venous thrombosis. Journal of Thrombosis and Haemostasis 2008;6(9):1474-7
3. Coppens M, Van Mourik JA, Eckmann CM, Büller HR, Middeldorp S. Current practise of testing for inherited thrombophilia. Journal of Thrombosis and Haemostasis 2007;5(9):1979-81
4. Coppens M, Kaandorp SP, Middeldorp S. Inherited thrombophilias. Obstetrics and Gynecology Clinics of North America 2006;33(3):357-74

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

☒ No

☐ Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

Funder	*Description of Research*	*My Role*	*End Date*

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

   ☐ Don't know

   ☒ No

   ☐ Yes

   If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

   ☐ Don't know

   ☒ No

   ☐ Yes

   If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

   I expect full support from my mentor and institution; Dr. Middeldorp, chair of this guideline, is part of my institution.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

   ☒ No

   ☐ Yes

   If yes, are you involved in formulating or voting for positions?

   ☐ No

   ☐ Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

☐ Don't know or not applicable

☐ No

☐ Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

   I am an internist vascular medicine with an emphasis on thrombosis as well as bleeding disorders.

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

   ☐ No

   ☒ Yes

   If yes, please explain:

   Ordering thrombophilia tests is regularly considered in my patients who have had any form of thrombosis.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

    ☒ No

    ☐ Yes

    If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Thrombophilia

Approved to participate?	*Status*	*Recusal may be required?*	*Reviewer name and date*	*Notes*
Yes	Unconflicted majority	No	4/20/15; 4/26/15	
Yes	Unconflicted majority	No	10/13/16 Alexander; 10/26/16 Kunkle	New financial disclosures. See Part D.
Yes	Unconflicted majority	No	03/20/2017 Alexander; 3/24/17 Kunkle	New disclosure. See Part D.
Yes	Unconflicted majority	No	5/22/2020 Alexander	New disclosures. See Part D.
Yes	Unconflicted majority	No	3/3/2022 Alexander	On 3/3/2022, Dr. Coppens confirmed all information in this form.
Yes	Unconflicted majority	No	11/29/2022 Kunkle	New disclosures. See Part D. Dr. Coppens also confirmed all other information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

Company	*Description*	*Disclosure Date*	*ASH Notes*

Notes:

Part D. New Declarations

The following interests were disclosed after appointment:

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
CSL Behring	50% compensation for travel, hotel accommodations and registration for July 2015 ISTH Congress	9/27/16	No COI. CSL Behring markets Kcentra (a warfarin reversal agent); however, these guidelines on thrombophilia are not expected to include recommendations about use of specific anticoagulants.
Bayer	50% compensation for travel, hotel accommodations and registration for July 2016 World Federation Hemophilia Congress	9/27/16	No COI. Bayer markets rivaroxaban; however, these guidelines on thrombophilia are not expected to include recommendations about use of specific anticoagulants.
Bayer	50% compensation for travel, hotel accommodations and registration for October 2016 Bayer Hematology Conference	9/27/16	No COI. Bayer markets rivaroxaban; however, these guidelines on thrombophilia are not expected to include recommendations about use of specific anticoagulants.
Boehringer Ingelheim	Sub investigator for registration (phase 3) trial of idarucizumab as a reversal agent for dabigatran etexilate	3/17/17	By email, Dr. Coppens reported that this study has ended. As described under Part A, Question 4, this research was not considered a conflict for these guidelines.
UniQure	Phase I/II study with AAV5-hFIX in patients with severe hemophilia B. Local investigator	5/22/20	Not a COI. UniQure does not market any products used in the diagnosis or treatment of VTE. Additionally,

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
	and member of publication committee		the subject of the research is unrelated to the guideline topic, Dr. Coppens does not have a leadership role, and all funding goes to his institution.
Portola	Travel and accommodation support for attending 2019 ASH annual meeting	5/13/2020	Not a COI. Portola markets betrixaban and andexanet alfa; however, these guidelines will not address use of specific anticoagulants.
Portola	Direct payment for advisory board participation. Subject: reversal of direct factor Xa inhibitors. Oct 2018.	5/13/2020	Not a COI. Portola markets betrixaban and andexanet alfa; however, these guidelines will not address use of specific anticoagulants.
CSL Behring	Direct payment for consulting. Travel and accommodation support for advisory board on hemophilia. December 2019.	5/13/2020	No COI. CSL Behring markets Kcentra (a warfarin reversal agent); however, these guidelines on thrombophilia are not expected to include recommendations about use of specific anticoagulants.
CSL Behring	Direct payment for speaking. Travel and accommodation support. May 2018	5/13/2020	Not a COI. CSL Behring markets Kcentra (a warfarin reversal agent); however, these guidelines on thrombophilia are not expected to include recommendations about use of specific anticoagulants.
Sobi	Direct payment for being judge on a grant	5/13/2020	Not a COI. Sobi does not market any

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
	proposal jury (once yearly from Nov 2018 onwards, ongoing)		products or devices used in the diagnosis or treatment of VTE.
NovoNordisk	Consultancy fee and travel support for Adboard on hemophilia (Sep 2019)	5/13/2020	Not a COI. NovoNordisk markets Novoseven, which is used off label to reverse anticoagulants; however, these guidelines will not include recommendations about the use of specific anticoagulants.
Pfizer	Fees for educational material on bleeding risk of anticoagulants with general practitioners (Aug 2019)	5/13/2020	Not a COI. Pfizer markets apixaban; however, these guidelines will not include recommendations about the use of specific anticoagulants.
Bayer	Lecturing fee on anticoagulation for arterial cardiovascular disease. Four different events for Dutch HCPs since April 2019.	5/13/2020	Not a COI. Bayer markets rivaroxaban; however, these guidelines will not include recommendations about the use of specific anticoagulants.
Daiichi Sankyo	Consultancy fee for Steering Committee membership for ETNA-VTE Europe, as well as fee for adjudication committee work (from 2016 onwards, meeting once a year, ongoing)	5/13/2020	Not a COI. Daiichi Sankyo markets edoxaban; however, these guidelines will not include recommendations about the use of specific anticoagulants.
Alexion	Lecturing fees on ESOC Satellite symposium 2022 and for internal	11/22/2022	Not a COI. Alexion does not market any products for

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
	Alexion purposes. All occurred during 2022.		thrombophilia testing or VTE treatment.
CSL Behring	Lecturing and consultancy fees on AAV gene therapy for haemophilia. Multiple initiatives. Ongoing.	11/22/2022	Not a COI. CSL Behring markets Kcentra (a warfarin reversal agent); however, these guidelines on thrombophilia are not expected to include recommendations about use of specific anticoagulants or about reversal.
Daiichi Sankyo	Member of steering committee ETNA-VTE. Payment for time attending meetings and reimbursement travel cost for being there. Ongoing, once per year meeting.	11/22/2022	Not a COI. Daiichi Sankyo markets edoxaban; however, these guidelines will not include recommendations about the use of specific anticoagulants.
Sobi	Jury member for award for small investigator initiated studies in the field of haemophilia and allied bleeding disorders in the Netherlands. Ongoing, once yearly.	11/22/2022	Not a COI. Sobi does not market any products for thrombophilia testing or VTE treatment.
Viatris	Paid participation in advisory board on low-molecular weight heparin. One time in 2022.	11/22/2022	Not a COI. Viatris does not market any products for thrombophilia testing or VTE treatment.
Daiichi Sankyo	The registry project described in Part A, Question 4, of this form ended >2 years ago.	11/22/2022	
Sanquin Blood Supply	The research project described in Part A, Question 4, of this form ended >2 years ago.	11/22/2022	

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
Boehringer Ingelheim	The phase 3 trial described in Part A, Question 4, of this form ended >2 years ago.	11/22/2022	
Anthos Therapeutics	Phase 3 studies of abelacimab for treatment of cancer associated VTE. Role: Center-PI.	11/22/2022	Not a COI. Abelacimab is not yet to market. Anthos has no other products.
Novo Nordisk	Frontier-2 study (Mim-8 for treatment of patients with severe haemophilia A). Role: Center-PI.	11/22/2022	Not a COI. Novo Nordisk markets Novoseven, which is used off label to reverse anticoagulants; however, these guidelines will not include recommendations about the use of specific anticoagulants.
Roche	HAVEN-6 study (emicizumab for non-severe haemophilia A.) Role: Center-PI	11/22/2022	Not a COI. Roche markets thrombophilia testing products. Dr. Coppens has a leadership role in research funded by this company. However, the subject of the research is unrelated to those products.
CSL Behring	Phase 3 study on gene therapy for haemophilia B. Role: Local PI, co-author on main publication	11/22/2022	Not a COI. CSL Behring markets Kcentra (a warfarin reversal agent); however, these guidelines on thrombophilia are not expected to include recommendations about use of specific anticoagulants or reversal.
UniQure	See CSL Behring. Study was initiated by	11/22/2022	Not a COI. See CSL Behring above.

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
	UniQure and this product including the study oversight has been taken over by CSL Behring		
Daiichi Sankyo	ETNA-VTE Europe (phase 4 study on edoxaban for VTE). Role: member of the steering committee	11/22/2022	Not a COI. Daiichi Sankyo markets edoxaban; however, these guidelines will not include recommendations about the use of specific anticoagulants.
	Dr. Coppens notes that he is no longer at the same institution as the guideline panel chair Dr. Middeldorp, as previously reported in Part B, Question 6.	11/22/2022	

ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each equity interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each patent or royalty interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes, as described below:

   Column 1 Name the company.

   Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

   Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

   Add rows as needed for each activity.

   To report activities that generate revenues for your institution, see Part B, Question 4.

Company	*Description*	*End Date*	*For ASH Internal Use*

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☐ No

   ☒ Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*
BMS/Pfizer	ADAM VTE study- RCT of apixaban vs dalteparin for cancer associated thrombosis	Coinvestigator	ongoing	Not a COI. BMS/Pfizer markets apixaban, however these guidelines on Thrombophilia will addressing Thrombophilia testing, are not expected to address specific anticoagulants. Additionally, Dr. Houghton does not have a leadership role and all funding goes to his institution.
BMS/Pfizer	EVE study- RCT of apixaban 2.5mg vs 5mg extended prophylaxis in cancer associated thrombosis	Coinvestigator	ongoing	Not a COI. BMS/Pfizer markets apixaban, however these guidelines on Thrombophilia will addressing Thrombophilia testing, are not expected to address specific anticoagulants. Additionally, Dr. Houghton does not have a leadership role and all funding goes to his institution.

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*
BMS/Pfizer	RCT – apixaban vs placebo for treatment of calf DVT	Coinvestigator	ongoing	Not a COI. BMS/Pfizer markets apixaban, however these guidelines on Thrombophilia will addressing Thrombophilia testing, are not expected to address specific anticoagulants. Additionally, Dr. Houghton does not have a leadership role and all funding goes to his institution.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

Company	*Description*	*End Date*	*For ASH Internal Use*

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Thrombophilia Guideline Panel

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

   ☒ No

   ☐ Yes

   If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

   ☒ No

   ☐ Yes

   If yes, what were those views and where were they made?

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

   ☐ No

☒ Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Funder	*Description of Research*	*My Role*	*End Date*
Mayo Clinic	Treatment of upper extremity DVT with DOACs	PI	ongoing
Mayo Clinic	Calf pump function and risk for venous thromboembolism	PI	ongoing

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don't know

☐ No

☒ Yes

If yes, please explain: Clinical consults for patients with venous and arterial thromboembolism and inherited and acquired thrombophilia.

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

   As long as those recommendations are based in fact and evidence, my institution, mentors, and colleagues would respect those conclusions.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

   ☒ No

   ☐ Yes

   If yes, are you involved in formulating or voting for positions?

   ☐ No

   ☐ Yes

   If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

   ☐ Don't know or not applicable

   ☐ No

   ☐ Yes

   If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?
   Hematology & Vascular Medicine

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

☐ No

☒ Yes

If yes, please explain: Clinical consults for patients with venous and arterial thromboembolism and inherited and acquired thrombophilia

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

☒ No

☐ Yes

If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Guideline Panel on Thrombophilia

Approved to participate?	*Status*	*Recusal may be required?*	*Reviewer Name and Date*	*Notes*
Yes	Unconflicted majority	No	11/26/2018 Alexander	Dr. Houghton does not have any current financial conflicts of interest.
Yes	Unconflicted majority	No	3/22/2019 Alexander	On 3/21/2019, Dr. Houghton confirmed all information in this form.
Yes	Unconflicted majority	No	5/5/2020 Alexander	On 5/1/2020, Dr. Houghton confirmed all information in this form.
Yes	Unconflicted majority	No	10/11/2022	On 10/3/2022, Dr. Houghton confirmed all information in this form (new disclosures in Part D below).

If status is conflicted minority, summarize all current material interests in affected companies:

Company	*Description*	*Disclosure Date*	*ASH Notes*

Notes:

Dr. Houghton disclosed research funding from Mayo Clinic for research related to the guideline topic. He also disclosed providing clinical consults for patients with venous and arterial thromboembolism and inherited and acquired thrombophilia.

Part D. New Declarations

The following interests were disclosed after appointment:

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
Moore Foundation	Funding from Moore Foundation for project related to quality improvement in diagnosis and risk stratification for pulmonary emboli	3/4/2022	Not a COI. The Moore Foundation is a non profit organization.
Mayo Clinic	Mayo Clinic: Artificial Intelligence INR management for Coumadin Clinics	3/4/2022	Not a COI.
Mayo Clinic	Mayo Clinic: Prediction of Pulmonary Embolism from ECG tracings using machine learning	3/4/2022	Not a COI.
Hemostasis and Thrombosis Research Society	Hemostasis and Thrombosis Research Society: Ultrasound shear wave elastography parameters of deep vein thrombosis and prediction of thrombus resolution	3/4/2022	Not a COI. Hemostasis and Thrombosis Research Society is a non profit organization.
The Hematologist	Payments from *The Hematologist* for writing articles	10/3/2022	Not a COI. *The Hematologist* is a publication by ASH, which is a nonprofit organization.
BMJ Online	Payment from BMJ Online for writing an article about	10/3/2022	Not a COI. *BMJ Online* is a nonprofit academic journal.

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
	antiphospholipid syndrome		
Hemostasis and Thrombosis Research Society	Mentored Research Grant from the Hemostasis and Thrombosis Research Society	10/3/2022	Not a COI. This is a nonprofit organization.
Mayo Clinic	Internal grants from Mayo Clinic to study the following: 1. Artificial Intelligence to predict cardiovascular disease from facial photographs 2. Development of machine learning techniques for management of warfarin and optimization of time in therapeutic range	10/3/2022	Not a COI. Mayo Clinic is a nonprofit organization.

ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each equity interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each patent or royalty interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No

☒ Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

Company	*Description*	*End Date*	*For ASH Internal Use*
Bayer	Consultancy, Advisory Board participation, Honoraria as Speaker	Occasional in the last 24 months; no ongoing contract	No COI. Bayer markets rivaroxaban; however, these guidelines on thrombophilia are not expected to address use of specific anticoagulants.
Biogen Idec	Consultancy, Advisory Board participation, Honoraria as Speaker	Occasional in the last 24 months; no ongoing contract	No COI. Biogen has no products that could be affected by guidelines on thrombophilia.

Company	*Description*	*End Date*	*For ASH Internal Use*
Pfizer	Honoraria as Speaker	Occasional in the last 24 months; no ongoing contract	No COI. Pfizer markets LMWHs; however, these guidelines on thrombophilia are not expected to address use of specific anticoagulants.
Octapharma	Consultancy, Advisory Board participation	Occasional in the last 24 months; no ongoing contract	No COI. Octapharma markets Octaplex, a reversal agent; however, these guidelines are not expected to address use of or reversal agents.
Baxter	Honoraria as Speaker	Occasional in the last 24 months; no ongoing contract	No COI. Baxter previously marketed heparins but no longer has any VTE-related products.

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No

☒ Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*
Pfizer	IIR – Characteristics of inhibitor patients in hemophilia A previously treated patients	PI	2014-June	Ended before appointment
Baxter	Meta-analysis of post-marketing authorization studies on Advate	Co-PI	2014-Nov	Ended before appointment
Novo-Nordisk	Systematic Review of Pharmacokinetic studies of treatment concentrates use in hemophilia A and B patients	PI	2014-Jun	Ended before appointment
Wilate	Observational registry of efficacy and safety of Wilate in patients with Hemophilia A	Local investigator	Ongoing	No COI. Wilate is a product of Octapharma. This company also makes Octaplex, a reversal agent; however, these guidelines are not expected to include recommendations about specific anticoagulants or reversal agents. Additionally, this is not a leadership role, and the research is unrelated to VTE.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

Company	*Description*	*End Date*	*For ASH Internal Use*

Alfonso Iorio, MD, PhD (McMaster University)

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Thrombophilia

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

   ☒ No

   ☐ Yes

   If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

   ☐ No

   ☒ Yes

   If yes, what were those views and where were they made?

   Review of the evidence with balanced view on potential roles and limitations

   Kenet G, Lütkhoff LK, Albisetti M, et al. Impact of Thrombophilia on Risk of Arterial Ischemic Stroke or Cerebral Sinovenous Thrombosis in Neonates and Children: A Systematic Review and Meta-Analysis of Observational Studies. Circulation 2010; 121:1838–47. doi:10.1161/CIRCULATIONAHA.109.913673

   Iorio A, Barnes C, Vedovati MC, et al. Thrombophilia and cerebral vein thrombosis. Front Neurol Neurosci 2008; 23:55–76. Doi: 10.1159/0000111261

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

☒ No

☐ Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Funder	*Description of Research*	*My Role*	*End Date*

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

   I would expect support, provided the guideline has been transparently evidence based.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

   ☒ No

   ☐ Yes

   If yes, are you involved in formulating or voting for positions?

   ☒ No

   ☐ Yes

   If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

   ☐ Don't know or not applicable

   ☒ No

   ☐ Yes

   If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

   Internal medicine, Clinical Chemistry and Biochemistry

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

   ☐ No

   ☒ Yes

   If yes, please explain:

   As a practicing clinician working in the field in thrombosis I occasionally prescribe thrombophilia screening; sometimes I counsel patients based on thrombophilia tests

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

    ☒ No

    ☐ Yes

    If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Guideline Panel on Thrombophilia

Approved to participate?	*Status*	*Recusal may be required?*	*Reviewer name and date*	*Notes*
Yes	Unconflicted majority	No	04/20/2015; 4/26/2015	Dr. Iorio has recent and current relationships with companies that make anticoagulation products; however, these guidelines are not expected to address specific anticoagulants.
Yes	Unconflicted majority	No	03/22/2017 Alexander; 3/24/2017 Kunkle	Dr. Iorio discloses continued consulting and speaking for companies that market anticoagulation products. See Part D.
Yes	Unconflicted majority	No	5/5/2020 Alexander	On 5/4/2020, Dr. Iorio confirmed all information in this form.
Yes	Unconflicted majority	No	3/11/2022 Alexander	New disclosures. See Part D.
Yes	Unconflicted majority	No	10/11/2022 Kunkle	On 9/29/2022, Dr. Iorio confirmed all information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

Company	*Description*	*Disclosure Date*	*ASH Notes*

Notes:

Part D. New Declarations

The following interests were disclosed after appointment:

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
Bayer	Direct payments for consulting, advisory board participation, speaking. This relationship was occasional until 18 months ago and there is no ongoing contract.	3/22/2017	Update to Part A Question 3. No COI. Bayer markets rivaroxaban; however, these guidelines on thrombophilia are not expected to address use of specific anticoagulants.
Biogen Idec	Direct payments for consulting, advisory board participation and speaking. This relationship was occasional until 18 months ago and there is no ongoing contract.	3/22/2017	Update to Part A Question 3. No COI. Biogen has no products that could be affected by guidelines on Thrombophilia.
Pfizer	Direct payments for speaking. This relationship was occasional until 18 months ago and there is no ongoing contract	3/22/2017	Update to Part A Question 3. No COI. Pfizer markets LMWHs and apixaban; however, these guidelines on thrombophilia are not expected to address use of specific anticoagulants.
Octapharma	Direct payments for consulting and advisory board participation. This relationship was occasional until 18 months ago and there is no ongoing contract.	3/22/2017	Update to Part A Question 3. No COI. Octapharma markets Octaplex, a reversal agent; however, these guidelines on thrombophilia are not expected to address use of specific anticoagulants.
Pfizer	Local PI for a study on gene therapy in	3/8/2022	No COI. Pfizer markets LMWHs and apixaban;

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
	hemophilia (2017 – 2019)		however, these guidelines on thrombophilia do not address use of specific anticoagulants.
Roche	Local PI for a study on Hemophilia Prophylaxis with Emicizumab. (2017 – 2019)	3/8/2022	Roache markets diagnostic tests for VTE. However, the subject of the research is not related to the guideline topic, Dr. Iorio does not have a leadership role, and all funding goes directly to his institution.
	Dr. Iorio disclosed: "Between 2017 and 2019 I have not accepted direct payment from industry, and any money for my consultant work or for speaking engagement was paid to McMaster University, and not to myself. From Jan 1 2020 onward, I have not received any money from industry at all, neither directly nor via McMaster."	3/8/2022	

ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each equity interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each patent or royalty interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No

☒ Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

Company	*Description*	*End Date*	*For ASH Internal Use*
Baxter	von Willebrand Disease Advisory Board	12/5/14 – 12/5/14	Ended before appointment
CSL Behring	von Willebrand Disease Advisory Board	11/14/2014	Ended before appointment
CSL Behring	Spoke at two von Willebrand disease educational symposiums	11/7 – 11/8, 2014 1-16 – 1/17, 2015	Ended before appointment

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

Company	*Description*	*End Date*	*For ASH Internal Use*

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

VTE in the Context of Pregnancy

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

   ☒ No

   ☐ Yes

   If yes, please explain: **None that I hope aren't based in the little evidence we have on the subject.**

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

   ☐ No

   ☒ Yes

   If yes, what were those views and where were they made? **I was head author on the American College of Obstetricians and Gynecologist Practice Bulletin on the subject. While I was head author, the guidelines were the work of many experts and did not represent my opinion(s) alone. A copy of the Practice Bulletin is attached as is the most recent review article I published on the subject.**

   4/14/2015 ASH Internal note: This is the citation: James, A. Practice Bulletin No. 123: Thromboembolism in Pregnancy. Obstetrics & Gynecology. 118(3): 718-729, September 2011.

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

☐ No

☒ Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Funder	*Description of Research*	*My Role*	*End Date*
NIH/CIHR	Pilot trial of postpartum thromboprophylaxis in high-risk women	Local Investigator	6/2014

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don't know

☐ No

☒ Yes

If yes, please explain: **I am consulted by hematologists and obstetricians about pregnant women with blood clots. Subsequently, they are often cared for by me and/or at my institution.**

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

   ☐ Don't know

   ☒ No

   ☐ Yes

   If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution? **Unaffected.**

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

   ☒ No

   ☐ Yes

   If yes, are you involved in formulating or voting for positions?

   ☐ No

   ☐ Yes

   If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

   ☐ Don't know or not applicable

   ☐ No

   ☐ Yes

   If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty? **Obstetrics and Gynecology, Maternal-Fetal Medicine**

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

   ☐ No

   ☒ Yes

   If yes, please explain: **I am consulted by hematologists and obstetricians about pregnant women with blood clots. Subsequently, they are often cared for by me and/or at my institution.**

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

    ☒ No

    ☐ Yes

    If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	VTE in the Context of Pregnancy; Thrombophilia

Approved to participate?	*Status*	*Recusal may be required?*	*Review Name and Date*	*Notes*
Yes	Unconflicted majority	No	04/14/2015; 4/16/2015	
Yes	Unconflicted majority	No	7/20/2018 Alexander	New disclosures. See Part D. On 7/18/2018, Dr. James confirmed all information in this form.
Yes (Thrombophilia)	Unconflicted majority	No	5/5/2020 Alexander	New disclosures. See Part D.
Yes (Thrombophilia)	Unconflicted majority	No	3/10/2022	New disclosures. See Part D.
Yes	Unconflicted majority	No	10/18/2022 Smith	New disclosures. See Part D,

If status is conflicted minority, summarize all current material interests in affected companies:

Company	*Description*	*Disclosure Date*	*ASH Notes*

Notes:

Part D. New Declarations

The following interests were disclosed after appointment:

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
Hemabiologics	Direct payment for consulting on reproductive issues in von Willebrand disease in May 2017	7/12/2018	Not a COI. Hemabiologics does not market any products or devices used in the diagnosis or treatment of VTE.
CSL Behring	Direct payment for serving on an advisory board on von Willebrand disease in June 2017	7/12/2018	Not a COI. CSL Behring markets Kcentra, a wayfaring reversal agent. However, warfarin is contraindicated in pregnant patients and these guidelines do not address its use. Additionally, the pregnancy panel had finished forming recommendations when this activity occurred. These thrombophilia guidelines will not address the use of specific anticoagulants.
American Regent	Direct payment for serving on an advisory board regarding the diagnosis and management of iron deficiency and iron deficiency anemia	5/2/2020	Not a COI. American Regent does not market any products or devices used in the diagnosis or treatment of VTE.
Coagulant Therapeutics	Research funding	3/2/2022	Not a COI. Coagulant Therapeutics does not market any products or devices used the diagnosis or treatment of VTE. Dr. James confirmed that this

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
			research is unrelated to the guideline topic.
Octapharma	Honorarium	3/2/2022	No COI. Octapharma markets Octaplex, a reversal agent; however, these guidelines on thrombophilia do not address use of specific anticoagulants.
Cerus	Honorarium	3/2/2022	Not a COI. Cerus Therapeutics does not market or produce any products used in testing for thrombophilia.
Tremeau	Honorarium	3/2/2022	Not a COI. Tremeau Therapeutics does not market or produce any products used in testing for thrombophilia.
HemoSonics	Honorarium	3/2/2022	HemoSonics does not appear to market or produce any products used in testing for thrombophilia.
Duke University	Employed as an emeritus professor	10/13/2022	
Coagulant Therapeutics	Grant support	10/13/2022	Not a COI. Coagulant Therapeutics does not market any products or devices used the diagnosis or treatment of VTE.
Cerus	Direct payment for participating in a advisory board on plasma-derived fibrinogen/cryoprecipitate product for hemorrhage	10/13/2022	Not a COI. Cerus Therapeutics does not market or produce any products used in testing for thrombophilia.

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
Octapharma	One time consult on plasma-derived von Willebrand concentrate in 2021	10/13/2022	No COI. Octapharma markets Octaplex, a reversal agent; however, these guidelines on thrombophilia do not address use of specific anticoagulants.
Tremeau	One time consult on nonsteroidal inflammatory drug for heavy menstrual bleeding in 2021	10/13/2022	Not a COI. Tremeau Therapeutics does not market or produce any products used in testing for thrombophilia.
NovoNordisk	One time consult recombinant factor Vlla for obsteric hemorrhage in 2021	10/13/2022	
HemoSonics	One time consult on coagulation laboratory analyzer in 2022	10/13/2022	HemoSonics does not appear to market or produce any products used in testing for thrombophilia.

ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, -treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each equity interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each patent or royalty interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No

☒ Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

Company	*Description*	*End Date*	*For ASH Internal Use*
Alberta Health Services	Employment	Current	Clinical employment is not considered a financial COI under ASH policy.
University of Calgary	Employment	Current	Academic employment is not considered a financial COI under ASH policy.
American Heart Association	Consulting	Current	Not a COI: AHA is a nonprofit organization.

Company	*Description*	*End Date*	*For ASH Internal Use*
AstraZeneca	One-time speaker on managing DOACs bleeding complication	Jan 2014	Ended before appointment
Bayer	One-time speaker on controversies in emergency care of Atrial fibrillation	Jun 2014	No COI. Bayer markets rivaroxaban; however, neither the thrombophilia guideline panel nor the diagnosis panel is expected to address use of specific anticoagulants. Furthermore, this interest ended before appointment.

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No

☒ Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*
Boehringer Ingelheim	Idarucizimab to reverse Dabigatran-related bleeding	Site investigator	Current	Not a COI: BI markets dabigatran; however, neither the thrombophilia guideline panel nor the diagnosis panel is expected to address use of specific anticoagulants. Furthermore, Dr. Lang does not have a leadership role in this research, the subject of the research is unrelated to thrombophilia or diagnosis of VTE, and on March 20, 2015, he explained that all funding for research activities goes to his institution.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

Company	*Description*	*End Date*	*For ASH Internal Use*

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Diagnosis of VTE

Thrombophilia

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

   ☒ No

   ☐ Yes

   If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

   ☒ No

   ☐ Yes

   If yes, what were those views and where were they made?

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

☒ No

☐ Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Funder	*Description of Research*	*My Role*	*End Date*

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

   Marginally positive or negative – in line with nature of the reactions.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

   ☒ No

   ☐ Yes

   If yes, are you involved in formulating or voting for positions?

   ☐ No

   ☐ Yes

   If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

   ☐ Don't know or not applicable

   ☐ No

   ☐ Yes

   If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

   Specialty: Family Medicine. Subspecialty: Emergency Medicine.

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

   ☐ No

   ☒ Yes

If yes, please explain:

Unless instructed by an internist or hematologist, I would not investigate for Thrombophilia and VTE.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

☒ No

☐ Yes

If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Guideline Panel on Thrombophilia Guideline Panel on Diagnosis of VTE

Approved to participate?	*Status*	*Recusal may be required?*	*Reviewer name and date*	*Notes*
Yes	Unconflicted majority	No	5/1/2015; 5/9/2015	
Yes	Unconflicted majority	No	9/25/2017 Alexander	New disclosures. See Part D.
Yes	Unconflicted majority	No	7/31/2018 Alexander	On 7/18/2018, Dr. Lang confirmed all information in this form.
Yes	Unconflicted majority	No	5/21/2020 Alexander	On 5/19/2020, Dr. Lang confirmed all information in this form.
Yes	Unconflicted majority	No	3/10/2022 Alexander	On 3/4/2022, Dr. Lang confirmed all information in this form.
Yes	Unconflicted majority	No	10/11/2022 Kunkle	On 9/13/2022, Dr. Lang confirmed all information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

Company	*Description*	*Disclosure Date*	*ASH Notes*

Notes:

Part D. New Declarations

The following interests were disclosed after appointment:

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
American Heart Association	Dr. Lang is no longer a consultant for this organization.	9/12/2017	Not a COI. This is an update to Part A, Question 3.
Thrombosis Canada	Executive Board member	9/12/2017	Not a COI. Thrombosis Canada is a non-profit organization and does not market any products related to VTE.

ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each equity interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each patent or royalty interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No

☒ Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

Company	*Description*	*End Date*	*For ASH Internal Use*
OF NOTE: all fees are being paid to our academic research institution and are being used to support research-associated costs; even though contracts on advisory or speaker activities state hourly fees, my salary is not being paid out of these fees.			
Aspen	Unrestricted educational grant for annual Thrombosis Masterclass in The Netherlands	Current	Disclosed 10/30/2014. No COI. All fees are paid to Dr. Middeldorp's institution. No personal income is received.
Astra Zeneca	Speaker fee EUR 1400	April 2014	Disclosed 10/30/2014 Ended before appointment.
Bayer	Advisory boards and speakers fees total maximum EUR 4000/year, intermittent contracts	April 2015	Disclosed 10/30/2014. Ended before appointment.

Company	*Description*	*End Date*	*For ASH Internal Use*
BMS/Pfizer	Advisory boards and speaker fees total maximum EUR 4000/year, intermittent contracts	September 2014	Disclosed 10/30/2014. Ended before appointment.
Boehringer Ingelheim	Advisory boards and speaker fees total maximum EUR 4000/year, intermittent contracts	September 2014	Disclosed 10/30/2014. Ended before appointment.
Daiichi Sankyo	Advisory boards and speaker fees total maximum EUR 4000/year, intermittent contracts	March 2015	Disclosed 10/30/2014. Ended before appointment.
GlaxoSmithKline	Unrestricted educational grant for annual Thrombosis Masterclass in The Netherlands	March 2013	Disclosed 10/30/2014. Ended before appointment.
GlaxoSmithKline	Speaker fees 2000 EUR	June 2013	Disclosed 10/30/2014. Ended before appointment.

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No

☒ Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*
Janssen	VTE prevention in medical patients trial. Maximum EUR 4000/year for NL services paid to my institution. Patient recruitment fees paid to my institution. Does not affect my salary.	National Lead (NL) for The Netherlands and site investigator	ongoing	Janssen markets rivaroxaban. Not a COI for thrombophilia panel: the subject of this research is somewhat related to thrombophilia. However, the guidelines are not expected to address use of specific anticoagulants. Not a COI for pregnancy panel: the subject of this research is not directly related to the guideline topic.
Daiichi Sankyo	VTE treatment trial in VTE patients with cancer. Patient recruitment fees paid to my institution. Does not affect my salary.	Site investigator.	ongoing	No COI. Daiichi Sankyo markets edoxaban. However, funding goes to Dr. Middeldorp's institution, and she does not have a leadership role in this research. Furthermore, the thrombophilia chapter is not expected to comment on specific AC, and the topic of research is not within scope of the chapter.
GSK, taken over by ASPEN	Grant for an investigator-sponsored study "Highlow study:	Principal Investigator	ongoing	Aspen markets danaparoid, and GSK

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*
	Low-molecular-weight heparin to prevent recurrent VTE in pregnancy: a randomized controlled trial of two doses" NCT (Clinicaltrials.gov) 01828697			markets argotraban and fondaparinux. Not a COI for thrombophilia panel: The subject of the research is not directly related to the guideline topic. Furthermore, the guidelines are not expected to address use of specific anticoagulants. **COI for VTE in the Context of Pregnancy:** GSK is an affected company + leadership role + topic of research within scope of chapter.
Portola	Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor who have Acute Major Bleeding. No fees established yet – if any these would go to institution and not affect my salary.	National Lead for The Netherlands	ongoing	Portola is developing an anticoagulant reversal agent. Not a COI for thrombophilia panel: the subject of the research is not directly related to the guideline topic. Furthermore, the guidelines are not expected to address use of reversal agents. **Potential COI for VTE in the Context of Pregnancy** (depends if the chapter addresses management of bleeding).

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*
Boehringer Ingelheim	REVERSE-AD. Idarucizumab for patients receiving dabigatran who need an antidote. Patient recruitment fees paid to my institution. Does not affect my salary.	Site investigator	ongoing	No COI. Boehringer Ingelheim markets dabigatran. However, funding goes to Dr. Middeldorp's institution, and she does not have a leadership role in this research.
Bayer	Einstein Choice study, rivaroban vs aspirin for long-term secondary prevention of VTE. Patient recruitment fees paid to my institution. Does not affect my salary.	Site investigator	ongoing	No COI. Bayer markets anticoagulants and aspirin. However, funding goes to Dr. Middeldorp's institution, and she does not have a leadership role in this research.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

Company	*Description*	*End Date*	*For ASH Internal Use*

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Topic	Guideline Panel
Venous thromboembolism (VTE)	VTE Guideline Coordination Panel
Thrombophilia	Guideline Panel on Thrombophilia
VTE in the context of pregnancy	Guideline Panel on VTE in the Context of Pregnancy

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

   ☐ No

   ☒ Yes

   If yes, please explain:

   I have strong opinions that relate to what I disclose and detail under point 2. Otherwise, I strongly believe in evidence-based medicine.

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

   ☐ No

   ☒ Yes (Disclosed 12/8/2015)

   If yes, what were those views and where were they made?

   1) I have a strong, in my view evidence-based opinion about the lack of high quality evidence on women's issues in thrombosis and hemostasis. This is particularly the case for the use of anticoagulants to prevent pregnancy complications, such as recurrent miscarriage, and recurrence of later pregnancy complications.

2) I have been asked to speak in debates on scientific meetings in the Netherlands about the efficacy and safety of NOACs and how this would translate to real life situations, the need (or no need) for antidotes, and so on.

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

☐ No

☒ Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Funder	*Description of Research*	*My Role*	*End Date*
French Ministry of Health PHRC National 2014	Funding for the French participation in Highlow study: Low-molecular-weight heparin to prevent recurrent VTE in pregnancy: a randomized controlled trial of two doses" NCT (Clinicaltrials.gov) 01828697	I am Principal Investigator of Highlow. The grant has been given to the French coordinators	ongoing
UK NHS NIHR RfPB	Funding of the UK participation in ALIFE2 study: Anticoagulants for living fetuses in women with recurrent miscarriage and inherited thrombophilia NTR 3361	I am Principal Investigator of ALIFE2. The grant has been given to the UK coordinators	ongoing

Funder	*Description of Research*	*My Role*	*End Date*
Netherlands Organisation for Scientific Research (NWO)	VIDI innovative research grant (NWO) 016.126.364. "Thrombophilia and reproduction: mechanisms and targeted interventions". This grant covers in part the ALIFE2 trial.	Personal grant, principal investigator	Ongoing, end date 2017
Netherlands Heart Foundation	CREW (DUTCH NATIONAL CONSORTIUM TO PROMOTE CARDIOVASCULAR HEALTHY AGING IN WOMEN). Development of female-specific prediction tools for VTE	Leader of the VTE part in work package 1	Ongoing, end date 2018

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

   ☐ Don't know

   ☒ No

   ☐ Yes

   If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

   ☐ Don't know

   ☒ No

   ☐ Yes

   If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

   I do not anticipate any strong involvement from the institutions – they would take it as it is and I am confident that they would support any evidence-based contributions regardless of reactions from peers. (Disclosed 12/8/2015)

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

   ☐ No

   ☒ Yes

   If yes, are you involved in formulating or voting for positions?

   ☒ No

   ☐ Yes

   If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

   ☐ Don't know or not applicable

   ☐ No

   ☒ Yes

   If yes, please explain:

   In the Netherlands we have written a letter to get NOACs reimbursed from basic health care insurance for patients with VTE (it is only reimbursed for AF). I have been representative of the Netherlands Society of Internal Medicine in these discussions with several stakeholders (not yet resolved). (Disclosed 12/8/2015)

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

   Vascular Medicine (Disclosed 12/8/2015)

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

   ☐ No

   ☒ Yes (Disclosed 12/8/2015)

   If yes, please explain: I am clinically active in the diagnosis, treatment and prevention of VTE.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

    ☐ No

    ☒ Yes

If yes, please describe: If anything, these would all be in line with what is disclosed. I do not anticipate to take on activities that will yield more financial revenues than already disclosed. Also, I avoid to be dominantly advising for a single company.

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Thrombophilia VTE in the Context of Pregnancy

Approved to participate?	*Status*	*Recusal may be required?*	*Reviewer name and date*	*Notes*
Yes (Thrombophilia)	Unconflicted majority	No	05/08/2015	Dr. Middeldorp has recent and current relationships with companies that make anticoagulation products; however, these guidelines are not expected to address use of specific anticoagulants.
Yes (VTE in the Context of Pregnancy)	Conflicted Minority	Yes	05/08/2015	
Yes (VTE in the Context of Pregnancy)	Conflicted minority		5/9/2018	Note: On 6/23/2017, FDA approved Portola's betrixaban and on 5/3/2018 FDA approved Portola's adexanet alfa. Dr. Middeldorp's relationship with Portola was previously labeled as a "potential COI". However, DOACs are considered out of scope for this panel, therefore this relationship is not considered a COI.
Yes			7/3/2018 Alexander	New disclosures. See Part D. Dr. Middeldorp confirmed all information in this form.
Yes (Thrombophilia)	Unconflicted majority	No	5/21/2020 Alexander	New disclosures. See Part D. On 5/15/2020, Dr. Middeldorp confirmed all information in this form.

Yes (Thrombophilia)	Unconflicted majority		3/10/2022 Alexander	On 3/7/2022, Dr. Middeldorp confirmed all information in this form.
Yes (Thrombophilia)	Unconflicted majority		10/19/2022 Smith; 11/30/2022 Kunkle	New disclosures. See Part D.

If status is conflicted minority, summarize all current material interests in affected companies:

Company	*Description*	*Disclosure Date*	*ASH Notes*
GSK (Aspen)	Principal investigator of "Highlow study: Low-molecular-weight heparin to prevent recurrent VTE in pregnancy: a randomized controlled trial of two doses" NCT (Clinicaltrials.gov) 01828697. All funds go to Dr. Middeldorp's institution.	05/08/2015	This COI is for VTE in the context of pregnancy. Aspen markets danaparoid, and GSK markets argotraban and fondaparinux. All funds go to Dr. Middeldorp's institution. However, she is the PI, and the subject of this study is directly relevant to the guideline topic.
Sanofi South Africa	Direct payment for speaking in September 2017	7/3/2018	This COI if for VTE in the Context of Pregnancy. Sanofi markets enoxaparin. This paid activity occurred after the recommendations were drafted.

Notes:

Part D. New Declarations

The following interests were disclosed after appointment:

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
Sanofi South Africa	Direct payment for speaking in September 2017	7/3/2018	Not a COI for thrombophilia. Sanofi markets enoxaparin and unfractionated heparin, however these guidelines on Thrombophilia are not expected to address specific anticoagulants. **COI for VTE in the Context of Pregnancy**. However, this paid activity occurred after the recommendations were drafted.
Daiichi Sankyo	Research funding for treatment of patients with acute pulmonary embolism. Started in 2017.	7/3/2018	Not a COI for thrombophilia. Daiichi Sankyo markets edoxaban, however these guidelines on Thrombophilia are not expected to address specific anticoagulants. Not a COI for VTE in the context of pregnancy. Daiichi Sankyo markets edoxaban, however DOACs were considered out of scope for this guideline. Additionally, all funding goes to Dr. Middeldorp's institution.
BMS-Pfizer	Caravaggio trial for treatment of patients with cancer and VTE. Started in 2018.	7/3/2018	Not a COI for thrombophilia. Pfizer markets dalteparin, however these guidelines on

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
			thrombophilia are not expected to address specific anticoagulants. Not a COI for VTE in the context of pregnancy. Dr. Middeldorp does not have a leadership role, and all funding goes to her institution. This activity occurred after the recommendations were drafted and would not have affected her recusal status.
Daiichi Sankyo	Research funding for investigator-initiated research on long-term effects of VTE in the context of the Hokusai VTE trial. Dr. Middeldorp is the PI and reports to the steering committee.	7/3/2018	Not a COI for thrombophilia. As above. Not a COI for VTE in the context of pregnancy. As above. Additionally, all funding goes to Dr. Middeldorp's institution, and she does not have a leadership role.
Bayer	Unrestricted grant for a DOAC registry, shared decision making and diagnostic management of CTEPJ. Dr. Middeldorp is the PI.	7/3/2018	Not a COI for thrombophilia. Bayer markets rivaroxaban, however these guidelines on thrombophilia are not expected to address specific anticoagulants. Not a COI for VTE in the context of pregnancy. DOACs are considered out of scope. Additionally, all funding goes to Dr. Middeldorp's institution.

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
Aspen	Unrestricted educational grant for annual Thrombosis Masterclass in The Netherlands (all fees paid to institution). This activity ended in 2016.	5/15/2020	Not a COI for thrombophilia. This is an update to Part A, Question 3.
Bayer	Direct payment for advisory boards and speaking	5/15/2020	Not a COI for thrombophilia. Bayer markets rivaroxaban, however, these guidelines on thrombophilia will not address use of specific anticoagulants.
BMS/Pfizer	Direct payments for advisory boards and speaking	5/15/2020	Not a COI for thrombophilia. BMS markets apixaban and Pfizer markets dalteparin, however, these guidelines on thrombophilia will not address use of specific anticoagulants.
Daiichi Sankyo	Direct payments for advisory boards and speaking	5/15/2020	Not a COI for thrombophilia. Daiichi Sankyo markets edoxaban, however, these guidelines on thrombophilia will not address use of specific anticoagulants.
Portola	Honoraria for attending investigator meetings and speakers fees	5/15/2020	Not a COI for thrombophilia. Portoloa markets betrixaban and andexanet alfa, however, these guidelines on thrombophilia will not

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
			address use of specific anticoagulants.
AbbVie	Honoraria for adjudication committees	5/15/2020	Not a COI for thrombophilia. AbbVie does not market any drugs or devices use in the diagnosis or treatment of VTE.
Sanofi	Honoraria for speaking	5/15/2020	Not a COI for thrombophilia. Sanofi market unfractionated heparin, however, these guidelines on thrombophilia will not address use of specific anticoagulants.
Janssen	VTE prevention in medical patients trial. Maximum EUR 4000/year for NL services paid to my institution. Patient recruitment fees paid to my institution. Does not affect my salary. This activity ended in 2018.	5/15/2020	Not a COI. This is an update to Part A, Question 4.
Daiichi Sankyo	VTE treatment trial in VTE patients with cancer. This activity ended in 2019.	5/15/2020	Not a COI. This is an update to Part A, Question 4.
GSK, taken over by ASPEN	Grant for an investigator-sponsored study “Highlow study: Low-molecular-weight heparin to prevent recurrent VTE in pregnancy: a	5/15/2020	Not a COI. This is an update to Part A, Question 4.

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
	randomized controlled trial of two doses" This activity ended in 2018.		
Portola	Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor who have Acute Major Bleeding. This activity ended in 2018.	5/15/2020	Not a COI. This is an update to Part A, Question 4.
Boehringer Ingelheim	REVERSE-AD. Idarucizumab for patients receiving dabigatran who need an antidote. This activity ended in 2016.	5/15/2020	Not a COI. This is an update to Part A, Question 4.
Bayer	Einstein Choice study, rivaroban vs aspirin for long-term secondary prevention of VTE. This activity ended in 2017.	5/15/2020	Not a COI. This is an update to Part A, Question 4.
Bayer	Unrestricted grant support for use of anticoagulants in special situations.	5/15/2020	Not a COI for thrombophilia. Bayer markets rivaroxaban, however, these guidelines on thrombophilia will not address use of specific anticoagulants.
Daiichi Sankyo	Unrestricted grant support for long term outcomes of patients treated with edoxaban or VKA	5/15/2020	Not a COI for thrombophilia. Daiichi Sankyo markets edoxaban, however, these guidelines on

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
			thrombophilia will not address use of specific anticoagulants.
	In January 2021, Dr. Middeldorp changed institutions: from Amsterdam UMC to Radboud University/Radboudumc.	10/15/2022	
Viatris	Speaker fees in November 2021 (1400 EUR)	10/15/2022	Not a COI. Viatris does not market any products for thrombophilia testing or VTE treatment.
Norgine	Speaker fees in July 2022 (2500 EUR)	10/15/2022	Norgine markets acenocoumarol, an anticoagulant. However, these guidelines on thrombophilia testing do not address use of specific anticoagulants.
Sanofi	Speaker fees in October 2022 (1012 EUR)	10/15/2022	Sanofi markets enoxaparin, an anticoagulant. However, these guidelines on thrombophilia testing do not address use of specific anticoagulants.
Sanofi	Speaker fees in December 2022 (1500 EUR)	10/15/2022	See above.
Astra Zeneca/Alexion/Portola	Steering Committee ANNEXA-4 and ANNEXA-1 studies. All feeds paid to my institution and do not affect my salary.	10/15/2022	These companies market various anticoagulants or reversal agents. However, these guidelines on thrombophilia testing do not address use of specific anticoagulants.

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
			Furthermore, these studies of reversal of anticoagulation are unrelated to thrombophilia testing.
Boehringer Ingelheim	Principle Investigator from 2022 onward; support for the investigator-initiated MEDEA study, a RCT of switching FXa inhibitor to dabigatran or addition of tranexamic acid. Paid to Amsterdam UMC, does not affect my salary.	10/15/2022	Boehringer Ingelheim markets dabigatran, an anticoagulant. However, these guidelines on thrombophilia testing do not address use of specific anticoagulants. Furthermore, this study is unrelated to thrombophilia testing.
Daiichi Sankyo	Principle Investigator in 2021; investigator-initiated long-term follow up study of patients treated with edoxaban or VKA. Paid to Amsterdam UMC, does not affect my salary.	10/15/2022	Daiichi Sankyo markets edoxaban, an anticoagulant. However, these guidelines on thrombophilia testing do not address use of specific anticoagulants. Furthermore, this study is unrelated to thrombophilia testing.
Pfizer	Principle Investigator in 2021; support for the investigator-initiated Highlow study. Paid to Amsterdam UMC, does not affect my salary.	10/15/2022	Pfizer markets the anticoagulants apixaban and dalteparin. However, these guidelines on thrombophilia will not address use of specific anticoagulants. Furthermore, this study is unrelated to thrombophilia testing.

ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each equity interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each patent or royalty interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No

☒ Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

Company	*Description*	*End Date*	*For ASH Internal Use*
Portola	Consulting honorarium	12/5/2015	Portola is developing an anticoagulation reversal agent (andexanet); however, these guidelines on thrombophilia are not expected to address use of specific anticoagulants.
CSL Behring	Consulting honorarium	12/17/2013	CSL Behring markets Kcentra, which is used for warfarin reversal. However, these guidelines are not expected to address use of specific anticoagulants or reversal agents. Furthermore, the interest ended before appointment.
Stago	Consulting honorarium	11/13/2013	Stago Diagnostics markets D-dimer kits. However, this interest ended before appointment.
Daiichi	Consulting honorarium	9/21/2013	Daiichi Sankyo markets edoxaban; however, these guidelines are not expected to address use of specific anticoagulants. Furthermore, this interest ended before appointment.

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No

☒ Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*
Portola	Phase 3 multicenter trial on reversal of antiXa anticoagulants; clinicaltrials.gov: NCT02329327	Local PI at Univ of NC	12/2017	Portola is developing an anticoagulation reversal agent (andexanet); however, these guidelines on thrombophilia are not expected to address use of specific anticoagulants or reversal agents. Furthermore, Dr. Moll does not have a leadership role in this research.
Daiichi	Phase 4 multicenter trial of use of Edoxaban in cancer patients with DVT. clinicaltrials.gov: NCT02073682	Local PI at Univ of NC	12/2018	Daiichi Sankyo markets edoxaban; however, these guidelines are not expected to address use of specific anticoagulants.

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*
				Furthermore, Dr. Moll does not have a leadership role in this research.
Boehringer-Ingelheim	Reversal of dabigatran with idarucizumab; clinicaltrials.gov: NCT02104947	Local PI at Univ of NC	12/2017	Boehringer-Ingelheim markets dabigatran; however, these guidelines are not expected to address use of specific anticoagulants. Furthermore, Dr. Moll does not have a leadership role in this research.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

Company	*Description*	*End Date*	*For ASH Internal Use*

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Thrombophilia

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

   ☒ No

   ☐ Yes

   If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

   ☐ No

   ☒ Yes

   If yes, what were those views and where were they made?

   Balanced review of the topic with clinical practical conclusions. Published: Moll S. Thrombophilia: clinical-practical aspects. J Thromb Thrombolysis. 2015 Apr; 39(3):367-78. doi: 10.1007/s11239-015-1197-3.

   Ongoing “Thrombophilia testing” guidance document development (I am the lead author of the thrombophilia chapter) by the *Anticoagulation Forum*; project headed by Dr. Jack Ansell; goal: publication 2015/2016 in J Thromb Thrombolys.

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

☒ No

☐ Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Funder	*Description of Research*	*My Role*	*End Date*

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

   Supportive. I don't foresee a problem.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

   ☒ No

   ☐ Yes

   If yes, are you involved in formulating or voting for positions?

   ☐ No

   ☐ Yes

   If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

   ☐ Don't know or not applicable

   ☐ No

   ☐ Yes

   If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?
   Hematology-Coagulation - Thrombosis

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

   ☐ No

   ☒ Yes

   If yes, please explain:

   I, as many other hematologists, order thrombophilia tests on a frequent basis and are part of my routine clinical practice. That's why these thrombophilia guidelines are being developed by ASH. Therefore, the guidelines will have an impact on my diagnostic testing pattern. After all, that's the purpose of guidelines.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

    ☒ No

    ☐ Yes

    If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Guideline Panel on Thrombophilia

Approved to participate?	*Status*	*Recusal may be required?*	*Reviewer name and date*	*Notes*
Yes	Unconflicted majority	No	5/1/15; 5/9/15	Dr. Moll has some financial relationships with anticoagulant manufacturers; however, these guidelines are not expected to address specific anticoagulants.
Yes	Unconflicted majority	No	10/13/16 Alexander; 10/26/16 Kunkle	New interests disclosed. See Part D.
Yes	Unconficted majority	No	3/20/17 Alexander; 3/24/17 Kunkle	New interest disclosed. See Part D.
Yes	Conflicted minority	Yes	5/22/2020 Alexander	New interest disclosed. See Part D.
Yes	Conflicted minority	Yes	3/10/2022 Alexander	New interests disclosed. See Part D.
Yes	Minority with conflicts	Yes	10/18/2022 Kunkle, Smith	Dr. Moll clarified dates of previously disclosed paid consulting. See Part D. He also confirmed all other information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

Company	*Description*	*Disclosure Date*	*ASH Notes*
Stago Diagnostica	Direct payment for consulting	5/21/2020	COI. Stago Diagnostica markets thrombophilia assays.

Company	*Description*	*Disclosure Date*	*ASH Notes*

Notes:

Part D. New Declarations

The following interests were disclosed after appointment:

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
Boehringer-Ingelheim	Direct payment for consulting (4/28/2016)	9/22/16	Boehringer-Ingelheim markets dabigatran; however, these guidelines are not expected to address use of specific anticoagulants.
Janssen	Direct payment for consulting (9/6/2018)	9/22/16	Janssen markets rivaroxaban; however, these guidelines are not expected to address use of specific anticoagulants.
Portola	Direct payment for consulting (2/11/2017)	03/20/17	Portola is developing an anticoagulation reversal agent (andexanet); however, these guidelines on thrombophilia are not expected to address use of specific anticoagulants or reversal agents.
Stago Diagnostica	Direct payment for consulting	5/21/2020	COI. Stago Diagnostica markets thrombophilia assay tests.
Pfizer	Direct payment for consulting (8/18/2016)	10/5/2022	Pfizer/BMS markets apixaban; however,

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
			these guidelines will not address use of specific anticoagulants.
Grifols	Direct payment for consulting (11/27/2017)	10/5/2022	Grifols markets antithrombin concentrate.
Janssen	Direct payment for consulting (9/6/2018)	10/5/2022	Janssen markets rivaroxaban; however, these guidelines are not expected to address use of specific anticoagulants.
Bristol-Myers Squibb	Direct payment for consulting (9/23/2021)	10/5/2022	Pfizer/BMS markets apixaban; however, these guidelines will not address use of specific anticoagulants.

ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each equity interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each patent or royalty interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

Company	*Description*	*End Date*	*For ASH Internal Use*

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

Company	*Description*	*End Date*	*For ASH Internal Use*

Tarra Myers

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Optimal Management of Anticoagulation Therapy

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

   ☒ No

   ☐ Yes

   If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

   ☒ No

   ☐ Yes

   If yes, what were those views and where were they made?

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

   ☒ No

   ☐ Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Funder	*Description of Research*	*My Role*	*End Date*

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

   The company I work for would be pleased to see the research and development that this program will produce. They value all aspects of health & safety and would support me in this health related panel.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

   ☒ No

   ☐ Yes

   If yes, are you involved in formulating or voting for positions?

   ☐ No

   ☐ Yes

   If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

   ☐ Don't know or not applicable

   ☐ No

   ☐ Yes

   If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

   I don't have a clinical specialty.

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

   ☒ No

   ☐ Yes

If yes, please explain:

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

☒ No

☐ Yes

If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Optimal Management of Anticoagulation Therapy

Approved to participate?	*Status*	*Recusal may be required?*	*Reviewer Name and Date*	*Notes*
Yes	Unconflicted majority	No	9/24/15; 9/25/15	
Yes	Unconflicted majority	No	7/2/2018 Alexander	On 6/29/2018, Ms. Myers confirmed all information in this form.
Yes	Unconflicted majority	No	5/5/2020 Alexander	On 5/1/2020, Ms. Myers confirmed all information in this form.
Yes	Unconflicted majority	No	3/10/2022 Alexander	On 3/3/2022, Ms. Myers confirmed all information in this form.
Yes	Unconflicted majority	No	10/11/2022 Kunkle	On 9/30/2022, Ms. Myers confirmed all information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

Company	*Description*	*Disclosure Date*	*ASH Notes*

Notes:
